Michael hakes - BNN - Top Pick Kneat (KSI TSX)
Most Recent buy: Feb 2022. $3.00
Kneat is a small software company based in Ireland and listed on the TSX. The market cap is about $230 million.
Its expertise is within the validation and compliance processes of the life science industry. Its software has been shown to dramatically improve cycle times and reduce process steps and site acceptance testing times.
Today, Kneat’s customer list includes eight of the world’s top 10 pharma companies and 62 total contracted customers and the largest pipeline in its history.
They are beginning to scale at several of its large pharma clients and this should continue for some time.